Cravath’s New York Office Moves to Two Manhattan West
Cravath partner D. Scott Bennett was featured as a “Dealmaker of the Year” in the April 2020 issue of The American Lawyer. Scott was selected for the annual feature in recognition of his role advising Novartis in connection with its $29.8 billion spin‑off of Alcon. The profile highlights the complexity of the deal, where there “was little roadmap,” and calls the matter “even more notable” given the Alcon business was “carved out of an even larger global company listed on two separate exchanges on two continents.”
Deals & Cases
April 10, 2019
On April 9, 2019, Novartis completed the spin-off of the Alcon eye care devices business into a separately-traded standalone company through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (“ADRs”), with each holder receiving 1 Alcon share for every 5 Novartis shares or ADRs held on April 8, 2019. Cravath represented Novartis in connection with this transaction, which is valued at approximately $29.8 billion based on first day trading of Alcon Inc.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.